PRINCETON, N.J.--(BUSINESS WIRE)--Certara, Inc., the global leader in biosimulation, today announced the release of version 20 of its Simcyp™ Physiologically-based Pharmacokinetic (PBPK) Simulator ...

Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global ...

Javelin Biotech today announced a landmark scientific publication, titled "Interconnected multi-microphysiological systems ...

According to MarketsandMarkets, the Biosimulation Market is projected to grow from about USD 4.27 billion in 2026 to USD 9.24 billion by 2031 ...

Introduction: To evaluate the accuracy of renal and tumor dosimetry for [¹⁷⁷Lu]Lu-PSMA-617 therapy using a single pre-therapy [⁶⁸Ga]Ga-PSMA-11 PET/CT scan with a hybrid framework integrating ...

Study in a Sentence: Researchers developed a computational “virtual twin” that uses patient-specific clinical data to predict how the cancer drug Fludarabine behaves in children undergoing bone marrow ...

a PK-Sim snapshot (*.json) file of the current PBPK model static content (e.g. text blocks, *.md files) as inputs for an evaluation plan an evaluation plan (evaluation-plan.json) to create an ...

Suraxavir marboxil (GP681) is an orally available prodrug that is converted in vivo to the active metabolite GP1707D07, a PA-targeting antiviral against influenza. Because GP1707D07 is primarily ...

Objectives: The pharmacokinetics (PK) of oligonucleotide therapeutics are governed by complex processes such as size-dependent tissue extravasation, renal clearance, and intracellular trafficking.

RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc., a global leader in biosimulation, today announced that the European Medicines Agency (EMA) has formally qualified the Simcyp® Simulator ...

Forbes contributors publish independent expert analyses and insights. I write about the economics of AI. The AI boom has been defined by unprecedented innovation across nearly every sector. From ...